Profil bibliographique

Daniel D. Mikol

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

111Publications signalées

7457Citations signalées

2Affiliations récentes

Institutions déclarées

Domaines associés

Migraine and Headache StudiesMultiple Sclerosis Research StudiesNeurological Complications and SyndromesVestibular and auditory disordersCerebrovascular and genetic disorders

Publications récentes

Accès ouvert 2025 articleOpenAlex

Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study

Stewart J. Tepper, David W. Dodick, Michel Lantéri‐Minet, David Doležil et autres

2 citationsEuropean Journal of Neurology

Accès ouvert 2025 articleOpenAlex

Lessons Learned and Recommendations from a SCOPE Spinal Cord Injury Neurorestorative Clinical Trials Update

Bethany R. Kondiles, Sabhya Rana, David B. Weiner, Armin Blesch et autres

4 citationsNeurotrauma Reports

Accès ouvert 2024 articleOpenAlex

Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine

Stewart J. Tepper, David W. Dodick, Michel Lantéri‐Minet, David Doležil et autres

27 citationsJAMA Neurology

2024 conference-abstractOpenAlex

NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with Spinal Cord Injury

Daniel D. Mikol, Judy Toews, Steven Mulcahy, Marc A. DePaul et autres

2 citationsArchives of Physical Medicine and Rehabilitation

Accès ouvert 2023 articleOpenAlex

Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis

Stewart J. Tepper, Richard B. Lipton, Stephen D. Silberstein, David Kudrow et autres

13 citationsHeadache The Journal of Head and Face Pain

2022 articleOpenAlex

A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)

Daniel D. Mikol, Marc A. DePaul, Betty Lawrence, Judy Toews et autres

1 citationAlzheimer s & Dementia

2022 articleOpenAlex

208 Long-term efficacy of erenumab in patients with chronic migraine who failed ≥3 prior prophylactic treatments

Mark W. Weatherall, Andreas R. Gantenbein, Shannon Ritter, Josefin Snellman et autres

0 citationsJournal of Neurology Neurosurgery & Psychiatry

2022 articleOpenAlex

A Placebo-Controlled Phase I Study of NVG-291 in Healthy Subjects, Targeting CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ) (S8.009)

Daniel D. Mikol, Betty Lawrence, Nana Collett, Judy Toews et autres

0 citationsNeurology

Accès ouvert 2022 articleOpenAlex

Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis

Messoud Ashina, Stewart J. Tepper, Jan Lewis Brandes, Uwe Reuter et autres

4 citationsHeadache The Journal of Head and Face Pain

Accès ouvert 2022 articleOpenAlex

Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double‐blind, placebo‐controlled studies

Koichi Hirata, Takao Takeshima, Fumihiko Sakai, Noboru Imai et autres

4 citationsBrain and Behavior

2022 articleOpenAlex

Reducing the physical, social, and emotional impact of episodic migraine: Results from erenumab STRIVE and ARISE phase III randomized trials

Ariane K. Kawata, Mary Kate Ladd, Richard B. Lipton, Dawn C. Buse et autres

9 citationsHeadache The Journal of Head and Face Pain

Accès ouvert 2021 articleOpenAlex

Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial

Koichi Hirata, Fumihiko Sakai, Takao Takeshima, Noboru Imai et autres

22 citationsThe Journal of Headache and Pain

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.